-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GuZiHvknciBUFhh8Jb+ZUXAiRS3h2i8E6Snd3qZ+fNt0YCisLb4dk3RpZXcuGG/R 7qkDUfP91jmiKsd5MhIOlw== 0001127602-08-004056.txt : 20080609 0001127602-08-004056.hdr.sgml : 20080609 20080609140703 ACCESSION NUMBER: 0001127602-08-004056 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080605 FILED AS OF DATE: 20080609 DATE AS OF CHANGE: 20080609 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OSI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000729922 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133159796 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 631-962-2000 MAIL ADDRESS: STREET 1: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: ONCOGENE SCIENCE INC DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SIMON ROBERT L CENTRAL INDEX KEY: 0001220050 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15190 FILM NUMBER: 08887662 MAIL ADDRESS: STREET 1: 58 S SERVICE RD CITY: MELVILLE STATE: NY ZIP: 11747 4 1 form4.xml PRIMARY DOCUMENT X0202 4 2008-06-05 0000729922 OSI PHARMACEUTICALS INC OSIP 0001220050 SIMON ROBERT L C/O OSI PHARMACEUTICALS, INC. 41 PINELAWN ROAD MELVILLE NY 11747 1 Exec. VP, Pharm. Dev. & Manf. Common Stock 2008-06-05 4 M 0 2300 21.50 A 27376 D Common Stock 2008-06-05 4 S 0 2300 40.00 D 25076 D Stock Option (Right to Buy) 21.55 2008-06-05 4 M 0 2300 0 D 2003-06-12 2012-06-11 Common Stock 2300 11500 D Transaction made pursuant to a 10b5-1 plan effective as of May 1, 2008. Includes the following shares acquired under the OSI Employee Stock Purchase Plan: (i) 125 shares acquired on December 31, 2007; and (ii) 170 shares acquired on March 31, 2008. One third of the stock option became exercisable one year after the date of the grant and the remainder vested ratably on a monthly basis over the succeeding 24 months. Includes only options with the same termination date. /s/ Michael G. Atieh, attorney-in-fact for Mr. Simon 2008-06-09 -----END PRIVACY-ENHANCED MESSAGE-----